Most viewed in the last 7 days from JAMA Cardiology: What is the optimal antiplatelet regimen in patients with ACS undergoing PCI who are at both high bleeding and ischemic risks? https://ja.ma/49UjIUM
JAMA Cardiology
Book and Periodical Publishing
Chicago, Illinois 25,337 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Cardiology is published online weekly, every Wednesday, and in 12 print/online issues a year. The journal receives more than 4.3 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal's acceptance rate is 10%. The median time to first decision is 10 days, and 60 days with review. The Journal Impact Factor is 24, one of the highest ranking among cardiology journals. All articles are published online first. Robert O. Bonow, MD, MS, the Max and Lilly Goldberg Distinguished Professor at Northwestern University Feinberg School of Medicine, is the inaugural editor in chief of JAMA Cardiology.
- Website
- https://jamanetwork.com/journals/jamacardiology
External link for JAMA Cardiology
- Industry
- Book and Periodical Publishing
- Company size
- 5,001-10,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 2015
- Specialties
- Valvular Heart Disease, Cardiology, Cardiothoracic Surgery, Depressive Disorders, Geriatrics, Psychiatry, Research, Methods, Statistics, Surgery, Cardiac Imaging, and Radiology
Updates
-
Most viewed in the last 7 days from JAMA Cardiology: Does plozasiran, an investigational APOC3-targeted small interfering–RNA therapeutic, safely and effectively reduce serum triglyceride level in patients with severe hypertriglyceridemia? https://ja.ma/3w5gTST
-
This Viewpoint discusses the impact of sinus node dysfunction and escape junctional rhythm associated with the Fontan procedure on patient outcomes. https://ja.ma/44gOxle
-
Analysis shows that initial declines in HF-related mortality from 1999 to 2012 have been entirely undone by subsequent reversals from 2012 to 2021, meaning that contemporary HF mortality rates are higher than in 1999. https://ja.ma/44gul38
-
Catheter ablation for AF was associated with reduced risk of HF events in patients with HFrEF but had limited or no benefit in HFpEF. https://ja.ma/3Uy3yw6
-
Cardiopulmonary exercise testing may be useful in characterizing distinct patterns of functional impairment across the spectrum of amyloid infiltration and predicting outcomes in patients with transthyretin amyloidosis. https://ja.ma/3Jf1Ysq
Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis
jamanetwork.com
-
A novel aortic stenosis polygenic risk score (PRS) performed comparably to most clinical risk factors in risk estimation of aortic stenosis. However, the addition of a PRS to clinical risk factors had only incremental improvement in risk estimation. https://ja.ma/3TL4nzK
Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis
-
Case report discusses a diagnosis of Leriche syndrome in a male patient with peripheral arterial disease, erectile dysfunction, and nonischemic cardiomyopathy. https://ja.ma/3Q8sGXv
-
Most viewed in the last 7 days from JAMA Cardiology: Does plozasiran, an investigational APOC3-targeted small interfering–RNA therapeutic, safely and effectively reduce serum triglyceride level in patients with severe hypertriglyceridemia? https://ja.ma/3U2KIvw
-
Among birisk patients with ACS who completed 9 to 12 months of DAPT after PCI, subsequent treatment with clopidogrel was superior to continuing DAPT with aspirin and clopidogrel in reducing clinically relevant bleeding. https://ja.ma/3Jkro7Y